Wells Fargo & Company Alx Oncology Holdings Inc Call Options Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALXO
# of Institutions
115Shares Held
38.4MCall Options Held
132KPut Options Held
19.7K-
Ven Bio Partners LLC San Francisco, CA9.7MShares$65.3 Million42.27% of portfolio
-
Redmile Group, LLC San Francisco, CA4.33MShares$29.1 Million1.9% of portfolio
-
Vivo Capital, LLC Palo Alto, CA4.22MShares$28.4 Million6.29% of portfolio
-
Cormorant Asset Management, LP Boston, MA3.14MShares$21.1 Million2.02% of portfolio
-
Orbimed Advisors LLC San Diego, CA2.72MShares$18.3 Million0.68% of portfolio
About ALX ONCOLOGY HOLDINGS INC
- Ticker ALXO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,747,100
- Market Cap $274M
- Description
- ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...